Targeting Anti-Beta-1-Adrenergic Receptor Antibodies for Dilated Cardiomyopathy
Key result
Therapies targeting anti-β1AR antibodies, which are present in 26% to 60% of patients with dilated cardiomyopathy, represent a promising avenue for future drug development.
Population
Patients with dilated cardiomyopathy (DCM)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
No immediate change to dilated cardiomyopathy care; leaves open targeted trials of anti-β1AR therapies.
Structured PICO
P
Population
Patients with dilated cardiomyopathy (DCM)
I
Intervention
Therapy directed against anti-beta-1-adrenergic receptor antibodies (anti-β1AR Abs), including immunoadsorption, small peptides, and nucleotide sequences
Targeting anti-beta-1-adrenergic receptor antibodies offers a promising therapeutic strategy for dilated cardiomyopathy, with recent advances focusing on specific neutralizing peptides and nucleotides.
Cite This Study
Patel et al. (2013) conducted a review in Dilated cardiomyopathy. Anti-beta-1-adrenergic receptor antibody targeted therapies was evaluated. Therapies targeting anti-β1AR antibodies, which are present in 26% to 60% of patients with dilated cardiomyopathy, represent a promising avenue for future drug development.